Aptorum Group Ltd Class A (APM) - Total Liabilities
Based on the latest financial reports, Aptorum Group Ltd Class A (APM) has total liabilities worth $4.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aptorum Group Ltd Class A (APM) investment intensity to see how much of total assets are deployed in long-term investments.
Aptorum Group Ltd Class A - Total Liabilities Trend (2016–2025)
This chart illustrates how Aptorum Group Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aptorum Group Ltd Class A (APM) total assets.
Aptorum Group Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Aptorum Group Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MEDICOX Co. Ltd
KQ:054180
|
Korea | ₩27.34 Billion |
|
Ireka Corporation Bhd
KLSE:8834
|
Malaysia | RM268.86 Million |
|
IMMUTABLE HOLDINGS INC.
F:B8X0
|
Germany | €185.77K |
|
CML Microsystems Plc
LSE:CML
|
UK | GBX14.82 Million |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
USA | $110.33 Million |
|
Ilika plc
LSE:IKA
|
UK | GBX2.35 Million |
|
Founder Group Limited Ordinary Shares
NASDAQ:FGL
|
USA | $159.49 Million |
|
Ecoclime Group AB Series B
ST:ECC-B
|
Sweden | Skr12.46 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Aptorum Group Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Aptorum Group Ltd Class A's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptorum Group Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptorum Group Ltd Class A (2016–2025)
The table below shows the annual total liabilities of Aptorum Group Ltd Class A from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.90 Million | +12.56% |
| 2024-12-31 | $4.35 Million | -17.19% |
| 2023-12-31 | $5.26 Million | -59.67% |
| 2022-12-31 | $13.03 Million | +196.15% |
| 2021-12-31 | $4.40 Million | -27.60% |
| 2020-12-31 | $6.08 Million | -33.22% |
| 2019-12-31 | $9.10 Million | -26.17% |
| 2018-12-31 | $12.33 Million | +826.46% |
| 2017-12-31 | $1.33 Million | +393.16% |
| 2016-12-31 | $269.84K | -- |
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more